Proteome Sciences Share Discussion Threads

[peverill] 22/10/2020 10:13

And again,what is wrong with him.????

[tom barnaby] 22/10/2020 08:34

Good morning all.

[stocktastic] 22/10/2020 07:48

Perverill Anything ia wise vs your guff that if the CEO is not posting RNSs to help you feel better, she cannot be doing anything Do you really expect any excitement when they do update?

[tom barnaby] 21/10/2020 20:03

Good evening Wrighty41.

[wrighty41] 21/10/2020 17:59

Thanks Colin. 2021 should be exciting times for shareholders buying at these levels. W41

[colinhy] 21/10/2020 17:55

Proteome Sciences TMT technology used in research to identify Covid-19 biomarkers ================================================================================= 20 October 2020 Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19 The COVID-19 pandemic is a global public health crisis. However,little is known about the pathogenesis and biomarkers of COVID-19. Herein, we profiled host responses to COVID-19 by performing plasma proteomics of a cohort of COVID-19 patients including non-survivors and survivors recovered from mild or severe symptoms, and uncovered numerous COVID-19-associated alterations of plasma proteins. We developed a machine learning-based pipeline to identify 11 proteins as biomarkers and a set of biomarker combinations, which were validated by an independent cohort and accurately distinguished and predicted COVID-19 outcomes. ---a total of 62 plasma samples were categorized into 7 batches and separately subjected to tandem mass tag (TMT) labeling (Table S2). For each batch, individual samples were labeled with TMT 11-plex reagents, and a pooling mixture of all the 62 samples was included and labeled as a standard control to eliminate the batch effect.--- Discussion The pandemic of COVID-19 has been one of the worst public health crises. It is of high priority to identify biomarkers that can monitor and predict the development of the disease and understand its pathogenesis. For this purpose, we conducted proteomics to profile plasma protein alterations in response to COVID-19 under different conditions, and identified 11 host proteins and a set of biomarker combinations that can serve as biomarkers by using the machine learning-based pipeline POC-19 developed by us. These biomarkers can classify and predict the outcomes of COVID-19. HTTPS://www.sciencedirect.com/science/article/pii/S1074761320304490

[peverill] 21/10/2020 17:50

I see he is still dishing out his wisdom.

[stocktastic] 21/10/2020 15:39

Ha, thanks elpirata. Time flies hey! Point still stands though Nothing embarrassing Golly on your scale of embarrassment!

[tom barnaby] 21/10/2020 15:11

BOL! How embarrassing.

[dominiccummings] 21/10/2020 13:32

Financial highlights: · Proteomics services revenues increased 71% to £0.60m (H1 2019: £0.35m) · TMT® reagent sales and royalties down 8% to £1.27m (H1 2019: £1.37m) · Total revenues increased 9% to £1.90m (H1 2019: £1.74m) · Gross profit increased 11% to £1.07m (H1 2019: £0.96m) · Costs increased 11% to £2.22m (H1 2019: £1.99m) · Loss before tax was £0.48m (H1 2019: £0.41m)

[elpirata] 21/10/2020 13:28

when the H1 results will be out soon anyway FAO stocktastic https://tinyurl.com/y6rd5bfr ;-))) !!

[stocktastic] 21/10/2020 13:13

"Morning all,still no sin of Mariola,strange for a new CEO to be so elusive when she runs the greatest gift to Proteomics on the planet.!!!" Perverill It remains possible that she is focused on selling business services - you would not be seeing that - rather than spending time on a pointless RNS just to make you feel happy, when the H1 results will be out soon anyway

[jeffian] 21/10/2020 12:43

"Several sources of positive newsflow to come in the following weeks and months, including stroke trial news and commercial licencing from Randox and possibly Galaxy." "News No News Available in the last month for PRM" Years? Decades?

[tom barnaby] 21/10/2020 11:39

#87808 I should imagine she is so busy taking fauxn calls from 'the stable' that she hasnt had time to start work yet.

[tom barnaby] 21/10/2020 11:38

Good morning monte1.

[tom barnaby] 21/10/2020 11:38

Good morning peverill.

[monte1] 21/10/2020 10:32

Mariella https://youtu.be/WPvLFDRufGk

[peverill] 21/10/2020 10:21

Morning all,still no sin of Mariola,strange for a new CEO to be so elusive when she runs the greatest gift to Proteomics on the planet.!!!

[monte1] 21/10/2020 10:19

I’ll put the bunting out.

[tom barnaby] 21/10/2020 10:01

We've had a trade, I note.

[monte1] 21/10/2020 09:59

Good morning Tom Barnaby

[tom barnaby] 21/10/2020 09:58

Good morning monte1.

[tom barnaby] 21/10/2020 09:58

Good morning colinhy.

[monte1] 21/10/2020 09:48

Good morning and thanks Colinhy. I can’t help thinking that yer c&p’s are becoming ever less frequent - are you sure you are still putting in the hours? Wouldn’t like to think that ye are slacking.

[colinhy] 21/10/2020 09:46

October 20 2020 Emerging mass spectrometry-based proteomics methodologies for novel biomedical applications With the latest advances for TMT, researchers can now even label up to 16 distinct samples with different TMT tags, pool them, and subsequently analyze them all in a single acquisition. Multiplexing can be increased to even higher levels in anticipation of newer reagents in the future. Isobaric labeling strategies TMT workflows and the various improved generations of reagents have greatly improved MS multiplexing capabilities for relative quantification of different experimental conditions. The significant reduction in the cost per acquisition make it more likely that TMT will be adopted in clinical tests or patient-specifi;c oncological mapping. Ultimately, in the future, we envision widespread implementation clinical MS and the development of personalized medicine employing these MS-based proteomics technologies. HTTPS://portlandpress.com/biochemsoctrans/article/doi/10.1042/BST20191091/226710/Emerging-mass-spectrometry-based-proteomics HTTPS://portlandpress.com/biochemsoctrans/article-pdf/doi/10.1042/BST20191091/895335/bst-2019-1091c.pdf